Pentixapharm completes rights offering, places 11,020,221 new shares for gross proceeds of about EUR 20.4 million

• Pentixapharm completed a rights offering, followed by a substantially oversubscribed private placement, issuing 11,020,221 new shares.
• Gross proceeds totaled about EUR 20.4 million; net proceeds were about EUR 19.65 million after estimated transaction costs.
• Share capital is set to rise to EUR 35,815,689 once the capital increase is registered.
• Proceeds earmarked for the PANDA Phase 3 program, US expansion, manufacturing and supply scale-up, platform development, working capital into Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2372300_en) on July 27, 2026, and is solely responsible for the information contained therein.